

# CITATION REPORT

List of articles citing

**Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case-control study**

**DOI: 10.1111/bcp.14227**

**British Journal of Clinical Pharmacology, 2020, 86, 1150-1164.**

**Source:** <https://exaly.com/paper-pdf/77210424/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
32	Five-Year Trends in Potential Drug Interactions with Direct-Acting Oral Anticoagulants in Patients with Atrial Fibrillation: An Australian-Wide Study. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	5
31	Non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation: safety issues in the elderly. <i>Expert Review of Clinical Pharmacology</i> , <b>2020</b> , 13, 1309-1327	3.8	2
30	Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case-control study. <i>British Journal of Clinical Pharmacology</i> , <b>2020</b> , 86, 1150-1164	3.8	22
29	Use of direct-acting oral anticoagulants in solid organ transplantation: A systematic review. <i>Pharmacotherapy</i> , <b>2021</b> , 41, 28-43	5.8	4
28	Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants-a Swedish, register-based cohort study in atrial fibrillation outpatients. <i>European Journal of Clinical Pharmacology</i> , <b>2021</b> , 77, 409-419	2.8	6
27	Appropriateness of direct oral anticoagulant dosing in patients with atrial fibrillation according to the drug labelling and the EHRA Practical Guide. <i>International Journal of Cardiology</i> , <b>2021</b> , 328, 97-103	3.2	2
26	The treatment effect of rivaroxaban on clot characteristics in patients who present acutely with first time deep vein thrombosis. <i>Clinical Hemorheology and Microcirculation</i> , <b>2021</b> ,	2.5	1
25	DOAC drug interactions and risk of major bleeding. <i>Drug and Therapeutics Bulletin</i> , <b>2021</b> , 59, 70	0.9	
24	Adverse drug reactions with oral anticoagulants: data from sicilian spontaneous reporting system database. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2021</b> , 46, 1027-1040	2.2	3
23	Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 684638	5.6	9
22	Association of Type of Antidepressant Initiation with Bleeding Risk in Atrial Fibrillation Patients Taking Oral Anticoagulants. <i>Drugs - Real World Outcomes</i> , <b>2021</b> , 8, 383-391	2.2	0
21	Pharmacogenetics of Bleeding and Thromboembolic Events in Direct Oral Anticoagulant Users. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 110, 768-776	6.1	6
20	Voorkamerfibrillatie en niet-vitamine K-antagonist orale anticoagulantia: van klinische studies tot gebruik in de dagelijkse praktijk. <i>Tijdschrift Voor Geneeskunde</i> ,	1	
19	Can direct oral anticoagulants be used in kidney transplant recipients?. <i>Clinical Transplantation</i> , <b>2021</b> , e14474	3.8	0
18	Risk of major bleeding associated with concomitant use of anticancer drugs and direct oral anticoagulant in patients with cancer and atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 1	5.1	1
17	Concomitant Use of NSAIDs or SSRIs with NOACs Requires Monitoring for Bleeding. <i>Yonsei Medical Journal</i> , <b>2020</b> , 61, 741-749	3	4
16	Prevalence and Factors Associated with Potential Drug-Drug Interactions in Older Community-Dwelling Adults: A Prospective Cohort Study. <i>Drugs and Aging</i> , <b>2021</b> , 38, 1025-1037	4.7	0

15	Assessment of direct oral anticoagulants administered as potentially inappropriate medications to elderly inpatients. <i>International Journal of Clinical Pharmacy</i> , <b>2020</b> , 42, 871-878	2.3	0
14	The OAC-PAD Risk Score Predicts Major Bleeding Events one Year after Hospitalisation for Peripheral Artery Disease.. <i>European Journal of Vascular and Endovascular Surgery</i> , <b>2022</b> ,	2.3	2
13	Impact of P-glycoprotein and/or CYP3A4-interacting drugs on effectiveness and safety of NOACs in patients with atrial fibrillation: a meta-analysis.. <i>British Journal of Clinical Pharmacology</i> , <b>2022</b> ,	3.8	1
12	[Predicting major bleeding events in patients with peripheral arterial disease: the OAC-PAD risk score].. <i>Gefasschirurgie</i> , <b>2022</b> , 1-4	0.3	0
11	Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-analysis.. <i>Annals of Medicine</i> , <b>2022</b> , 54, 80-97	1.5	2
10	Evaluating pharmacokinetic drug-drug interactions of direct oral anticoagulants in patients with renal dysfunction.. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2022</b> , 1-14	5.5	
9	Effect of tramadol and DOACs with special attention to dabigatran on concomitant use, on the risk of major bleeding using BIFAP database in Spain.		0
8	Concomitant use of selective serotonin reuptake inhibitors and oral anticoagulants and risk of major bleeding: a systematic review and meta-analysis.		0
7	DOAC drug interactions management resource. 171516352211161		0
6	Risk of bleeding among individuals on direct acting oral anticoagulants: an academic medical center cohort study.. <b>2022</b> , Publish Ahead of Print,		0
5	Anticoagulant therapy with direct oral anticoagulants in the context of polypharmacy: a course to safety. <b>2022</b> , 52-64		0
4	Selective serotonin reuptake inhibitor use and risk of major bleeding during treatment with vitamin K antagonists: results of a cohort study.		0
3	Drug-drug interactions with direct oral anticoagulants: development of a consensus list for ambulatory care.		1
2	Drug-drug interactions with direct oral anticoagulants for the prevention of ischemic stroke and embolism in atrial fibrillation: a narrative review of adverse events. <b>2023</b> , 16, 313-328		0
1	Impact of Selective Serotonin-Reuptake Inhibitors in Hemorrhagic Risk in Anticoagulated Patients Taking Non-vitamin K Antagonist Anticoagulants. Publish Ahead of Print,		0